Investor sentiment turns negative as MacroGenics reports trial deaths

13 May 2024
macrogenics_large

Despite a lower dose, data from the Phase II stage of the TAMARACK study have raised concerns over the safety profile of MacroGenics’ (Nasdaq: MGNX) antibody-drug conjugate (ADC), vobra duo.

The company reported five deaths in the trial, with a grade 3 or worse adverse event affecting more than half of patients.

While two of the fatalities were deemed unrelated to the test drug, three deaths in the higher dose arm remain under investigation by trial monitors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology